Pablo Perel Selected Research

Tranexamic Acid (AMCA)

6/2014	Red blood cell transfusion and mortality in trauma patients: risk-stratified analysis of an observational study.
7/2013	Tranexamic acid in trauma: we need stronger global health policy.
1/2013	Tranexamic acid for reducing mortality in emergency and urgent surgery.
9/2012	Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial.
8/2012	Predicting early death in patients with traumatic bleeding: development and validation of prognostic model.
6/2012	CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial.
5/2012	Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
3/2012	Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial.
5/2011	Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
3/2011	The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pablo Perel Research Topics

Disease

16	Cardiovascular Diseases (Cardiovascular Disease) 06/2022 - 12/2011
14	Hemorrhage 01/2020 - 01/2007
12	Wounds and Injuries (Trauma) 06/2014 - 01/2010
8	Hypertension (High Blood Pressure) 07/2022 - 01/2013
8	Stroke (Strokes) 06/2022 - 05/2012
6	Craniocerebral Trauma (Head Injury) 05/2012 - 01/2007
4	Myocardial Infarction 06/2022 - 05/2012
3	Atrial Fibrillation 01/2020 - 04/2014
3	Critical Illness (Critically Ill) 02/2013 - 03/2011
3	Burns 02/2013 - 03/2011
3	Traumatic Brain Injuries (Traumatic Brain Injury) 06/2012 - 01/2010
2	Heart Failure 01/2021 - 04/2014
2	Peripheral Arterial Disease 01/2017 - 04/2014
2	Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis) 10/2015 - 10/2015
2	Pulmonary Embolism 01/2013 - 05/2012
2	Venous Thrombosis (Deep-Vein Thrombosis) 01/2013 - 05/2012
2	Thrombosis (Thrombus) 01/2013 - 12/2011
2	Infections 02/2010 - 02/2010
1	Renal Insufficiency (Renal Failure) 01/2022
1	Coronary Disease (Coronary Heart Disease) 01/2022
1	Acute Kidney Injury (Acute Renal Failure) 01/2021
1	Chronic Disease (Chronic Diseases) 01/2020
1	Embolism (Embolus) 01/2020
1	Periodontitis 01/2020
1	Atherosclerosis 11/2017
1	Chest Pain (Chest Pains) 04/2017
1	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2017
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2017
1	Hypercholesterolemia 01/2017
1	Heart Diseases (Heart Disease) 11/2016
1	Weight Gain 10/2015
1	Vascular Diseases (Vascular Disease) 06/2015
1	Neoplasms (Cancer) 04/2014
1	Liver Diseases (Liver Disease) 04/2014
1	Lung Diseases (Lung Disease) 04/2014
1	Chronic Renal Insufficiency 04/2014
1	Seizures (Absence Seizure) 01/2013
1	Breast Neoplasms (Breast Cancer) 01/2013
1	Shock 01/2013
1	Obesity 01/2013
1	Diabetes Mellitus 01/2013
1	Coma (Comas) 03/2011
1	Virus Diseases (Viral Diseases) 02/2010
1	Hypotension (Low Blood Pressure) 08/2008

Drug/Important Bio-Agent (IBA)

13	Tranexamic Acid (AMCA)FDA Link 06/2014 - 01/2010
6	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2012 - 01/2007
4	CholesterolIBA 01/2022 - 01/2017
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 01/2019
3	Colloids (Colloid)IBA 02/2013 - 03/2011
3	Antifibrinolytic Agents (Antifibrinolytics)IBA 01/2013 - 01/2007
2	Antihypertensive Agents (Antihypertensives)IBA 01/2022 - 01/2019
2	AnticoagulantsIBA 01/2021 - 01/2020
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021 - 12/2019
2	Vitamin K FDA Link 01/2021 - 01/2020
2	Indicators and Reagents (Reagents)IBA 12/2019 - 01/2013
2	LipidsIBA 04/2017 - 04/2014
1	Drug CombinationsIBA 07/2022
1	C-Reactive ProteinIBA 01/2022
1	omega-Chloroacetophenone (Mace)IBA 01/2022
1	Troponin IIBA 01/2022
1	N 30IBA 01/2022
1	Oxygen (Dioxygen)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 10/2021
1	Warfarin (Coumadin)FDA LinkGeneric 01/2020
1	11-dehydro-thromboxane B2IBA 12/2019
1	Angiotensin Receptor AntagonistsIBA 12/2019
1	Blood Glucose (Blood Sugar)IBA 01/2019
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2019
1	Anti-Arrhythmia AgentsIBA 11/2016
1	UK 1IBA 01/2016
1	GlucocorticoidsIBA 10/2015
1	Methylprednisolone FDA LinkGeneric 10/2015
1	CreatinineIBA 04/2014
1	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 01/2013
1	Tamoxifen FDA LinkGeneric 01/2013
1	HDL CholesterolIBA 01/2013
1	HDL LipoproteinsIBA 01/2013
1	Lipoproteins (Lipoprotein)IBA 01/2013
1	Cytochrome P-450 CYP2C19IBA 12/2011
1	Clopidogrel (Plavix)FDA Link 12/2011
1	EnzymesIBA 12/2011
1	Aprotinin (Trasylol)FDA Link 01/2010
1	Aminocaproic Acid (6 Aminocaproic Acid)FDA LinkGeneric 01/2010
1	Factor VIIa (Activated Factor VII)IBA 01/2010
1	recombinant FVIIa (rFVIIa)FDA Link 01/2010
1	Glucose (Dextrose)FDA LinkGeneric 08/2008

Therapy/Procedure

12	Therapeutics 07/2022 - 10/2015
11	Secondary Prevention 06/2022 - 06/2015
7	Blood Transfusion (Blood Transfusions) 01/2013 - 02/2010
3	Resuscitation 02/2013 - 03/2011
2	Continuity of Patient Care 01/2020 - 01/2017
1	Mechanical Ventilators (Ventilator) 01/2021
1	Complementary Therapies (Alternative Medicine) 01/2021
1	Drug Therapy (Chemotherapy) 01/2018
1	Electric Countershock (Cardioversion) 11/2016
1	Catheter Ablation 11/2016
1	Erythrocyte Transfusion 06/2014
1	Stents 12/2011
1	Critical Care (Surgical Intensive Care) 05/2011
1	Time-to-Treatment 03/2011